2024    2023    2022    2021    2020    2019    2018    2017    2016   

2021

Articles

221 - 

Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study

Florian Lemaitre, Fabien Fily, Jean-Baptiste Foulquier, Matthieu Revest, Vincent Jullien et al.

Biomedicine and Pharmacotherapy, 2021, 142, pp.112053.

DOI : https://doi.org/10.1016/j.biopha.2021.112053

Pubmed : 34435591

 

222 - 

DRUG TRANSPORTERS EXPRESSION IS ASSOCIATED WITH TACROLIMUS INTRACELLULAR CONCENTRATION

Florian Lemaitre, Gwendal Coste, Jonathan Chemouny, Pauline Houssel-Debry, Mikaël Roussel et al.

Transplant International, 2021, 34, pp.344-344.

 

223 - 

Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer

Priscilla Leon, Geraldine Cancel-Tassin, Violaine Bourdon, Bruno Buecher, Stephane Oudard et al.

Prostate, 2021, 81 (6), pp.318-325.

DOI : https://doi.org/10.1002/pros.24109

Pubmed : 33599307

 

224 - 

Contribution of Long-Term Exposure to Outdoor Black Carbon to the Carcinogenicity of Air Pollution: Evidence regarding Risk of Cancer in the Gazel Cohort

Emeline Lequy, Jack Siemiatycki, Kees de Hoogh, Danielle Vienneau, Jean-François Dupuy et al.

Environmental Health Perspectives, 2021, 129 (3), pp.37005.

DOI : https://doi.org/10.1289/EHP8719

Pubmed : 33759553

 

225 - 

Vers une meilleure compréhension de l’étiologie des maladies auto-immunes systémiques : une maladie systémique doit-elle toujours être définie comme une « maladie inflammatoire diffuse d’origine inconnue » en 2021 ? Exemple de l’exposition à la silice cristalline Toward a better understanding of the etiology of systemic autoimmune diseases : should a systemic disease still be defined as a "diffuse inflammatory disease of unknown origin" in 2021? Example of crystalline silica exposure

A Lescoat, Catherine Cavalin, V Lecureur, P Jégo

Vers une meilleure compréhension de l’étiologie des maladies auto-immunes systémiques : une maladie systémique doit-elle toujours être définie comme une « maladie inflammatoire diffuse d’origine inconnue » en 2021 ? Exemple de l’exposition à la silice cristalline. La Revue de Médecine Interne, 2021, 42 (4), pp.233-236.

DOI : https://doi.org/10.1016/j.revmed.2021.03.005

Pubmed : 33781611

 

226 - 

Occupational exposure to respirable crystalline silica and autoimmunity: sex differences in mouse models

Alain Lescoat, Alice Ballerie, Valérie Lecureur

International Journal of Epidemiology, 2021, 50 (4), pp.1396-1397.

DOI : https://doi.org/10.1093/ije/dyab125

Pubmed : 34263319

 

227 - 

Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol

Alain Lescoat, David Roofeh, Whitney Townsend, Michael Hughes, Robert D. Sandler et al.

BMJ Open, 2021, 11 (3),

DOI : https://doi.org/10.1136/bmjopen-2020-044765

Pubmed : 33707273

 

228 - 

New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine

Alain Lescoat, John Varga, Marco Matucci-Cerinic, Dinesh Khanna

Expert Opinion on Investigational Drugs, 2021, 30 (6), pp.635-652.

DOI : https://doi.org/10.1080/13543784.2021.1923693

Pubmed : 33909517

 

229 - 

Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study

Alain Lescoat, Marie Leroy, Guillaume Coiffier, Claire Cazalets, Nicolas Belhomme et al.

Joint Bone Spine, 2021, 88 (5), pp.105214.

DOI : https://doi.org/10.1016/j.jbspin.2021.105214

Pubmed : 34102595

 

230 - 

Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes

Alain Lescoat, S Murphy, David Roofeh, John D. Pauling, Michael Hughes et al.

Journal of Scleroderma and Related Disorders, 2021, 6 (1), pp.66-76.

DOI : https://doi.org/10.1177/2397198320961967

Pubmed : 34316516